新穎性喜樹鹼衍生物801對人類肝癌細胞株HA22T/VGH的細胞毒殺效用

肝癌一直是國人惡性腫瘤死因的第一順位,除了與B型肝炎的盛行率高有關外治療上大約只有30%的肝癌患者可以接受手術切除,手術後的高復發率以及藥物治療效果不佳,使得肝癌的治療一直是個難題。本實驗以SRB方式證實喜樹鹼(CPT, camptothecin) 能抑制肝癌細胞的增生及誘導其凋亡，因此希望能藉由研究喜樹鹼及其衍生物，來了解其是否能抑制人類肝癌HA22T�VGH細胞的細胞毒性，並探討機制期望能應用在癌症的臨床治療上。首先, 我們將喜樹鹼以不同濃度作用于人肝癌HA22T�VGH細胞.用SRB觀察其細胞生長,發現可抑制細胞生長。因此我們再利用Liu’s stain觀察細胞型態,當藥物濃度愈高時除細胞數減少之外,漂浮的細胞變多,而且細胞有變大的現象出現。接著使用PI(propidium iodide)染色法觀察細胞型態,發現染色體濃縮細胞核萎縮、細胞膜皺縮等等。然後利用流式細胞儀和PI染色證明喜樹鹼誘導細胞凋亡。另外,西方墨點法證實喜樹鹼活化caspase3, caspase9和PARP因而誘導細胞凋亡。綜合上述結果,可發現喜樹鹼及其衍生物對于人肝癌HA22T�VGH細胞的毒殺是有效的,在未來或許可以應用在肝癌臨床上治療與預防。

關鍵字

喜樹鹼衍生物801 ；人類肝癌細胞株HA22T/VGH

並列摘要

Liver cancer cause of death in people has been the first priority, in addition to the prevalence of hepatitis B Rate related to the external treatment, only about 30% of liver cancer patients can undergo surgery resection, surgery After high recurrence rate and poor drug treatment, making treatment of liver cancer has been a problem. In this experiment confirmed SRB way camptothecin (CPT, camptothecin) can inhibit liver cancer cell proliferation and induce apoptosis, thus hoping to camptothecin and its derivatives by research to see if it can inhibit human hepatoma HA22T / VGH cytotoxic cells and investigate the mechanism of expectations can be applied in the clinical treatment of cancer. First, we will act on different concentrations of camptothecin in human hepatoma HA22T / VGH cells with SRB observe cell growth, found to inhibit cell growth. Therefore, we reuse Liu's stain cell morphology was observed when the drug concentration is higher than when the addition to reducing the number of cells, the floating cells is increased, and the cell becomes large phenomenon. Then use the PI (propidium iodide) staining cell types found chromosome condensation Nucleus atrophy, cell shrinkage and so on. Then using flow cytometry and PI staining proved camptothecin-induced apoptosis. In addition, the Western blot confirmed that camptothecin activated caspase3, caspase9 and PARP thus inducing apoptosis. Based on the results, can be found camptothecin and its derivatives for human hepatoma HA22T / VGH cell killing is effective in the future may be able to apply on the clinical treatment of liver cancer and prevention.

並列關鍵字

Camptothecin derivate(801) ； Hepatoma HA22T/VGH cell line

參考文獻

1. Asim, M., et al., Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clin Biochem, 2011. 44(14-15): p. 1235-40.

2. Robinson, W.S., Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med, 1994. 45: p. 297-323.

3. Morgan, T.R., S. Mandayam, and M.M. Jamal, Alcohol and hepatocellular carcinoma. Gastroenterology, 2004. 127(5 Suppl 1): p. S87-96.

4. Beasley, R.P., Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 1988. 61(10): p. 1942-56.

5. Dixon, L.J., et al., Kupffer cells in the liver. Compr Physiol, 2013. 3(2): p. 785-97.

國際替代計量

新穎性喜樹鹼衍生物801對人類肝癌細胞株HA22T/VGH的細胞毒殺效用

全文下載

主題瀏覽